MAIA Biotechnology Highlights Ongoing Clinical Advancements
Company confirms 12 patients enrolled in Phase 2 THIO-101 as expansion trial adds new regions
Posters available for Phase 2 and Phase 3 clinical trials
CHICAGO — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical enterprise dedicated to developing innovative immunotherapies for cancer, shared significant updates from two poster presentations at the Society for Immunotherapy of Cancer conference. This notable gathering occurred recently in National Harbor. The posters spotlight the progress of MAIA’s clinical trials, namely the Phase 2 THIO-101 expansion trial and the Phase 3 THIO-104 trial. These trials aim to evaluate the safety and efficacy of ateganosine, a groundbreaking telomere-targeting agent, specifically for non-small cell lung cancer (NSCLC).
MAIA’s Senior Medical Director, Victor Zaporojan, M.D., remarked on the significance of participating in such a pivotal event during its 40th anniversary. He stated, “SITC serves as an essential platform to showcase the achievements of our Phase 2 clinical trial, which is gaining traction. With patient enrollment now reaching new heights in areas designated by the European Medicines Agency (EMA), we currently have 12 patients as part of the expansion, and we are optimistic about the near-term progress.”
Encouragingly, the company has initiated patient screening for the Phase 3 trial, THIO-104. MAIA’s CEO, Vlad Vitoc, M.D., expressed enthusiasm regarding the response from healthcare professionals involved in these clinical sites, recognizing the pressing need for effective treatments in third-line NSCLC patients, who often show poor prognoses from existing therapies. With previous trials indicating promising overall survival rates with ategadosine, a new hope points toward an efficient FDA approval pathway.
The details shared at SITC showcase both Phase 2 and Phase 3 trial designs featuring ateganosine, which will be preceded by cemiplimab (Libtayo). MAIA’s commitment to ensuring patient well-being is reinforced by a recent success story: a participant treated in March 2023 during the THIO-101 trial exhibited remarkable survival beyond 30 months.
Dr. Tomasz Jankowski, a prominent investigator for THIO-101, highlighted the potential of ateganosine to revolutionize treatment options in Poland for advanced NSCLC patients. “With ongoing research directed at improving outcomes for this disease, ateganosine could redefine therapeutic strategies, providing newfound optimism for both patients and medical practitioners.”
The findings at SITC were filed in a Current Report with the Securities and Exchange Commission (SEC). For those interested in further details regarding these presentations and the company’s accomplishments, resources can be accessed via the SEC’s official website along with MAIA’s own site.
About Ateganosine and Its Clinical Trials
Ateganosine is regarded as a pioneering telomere-targeting compound currently under clinical evaluation for its capability to combat non-small cell lung cancer (NSCLC). Telomeres and telomerase play critical roles in sustaining cancer cell life, yet, ateganosine’s distinct mechanism of action promotes telomere modification and cancer cell apoptosis, leading to spontaneous immune responses in the body.
The THIO-101 Phase 2 clinical trial emerged as a core study in assessing ateganosine’s effectiveness as an adjunct therapy to immune checkpoint inhibitors following chemotherapy treatment. The trial primarily examines both the safety profile and overall therapeutic effect, aiming to augment and sustain immune responses in patients resistant to prior therapies. This trial paves the way for evaluating real-world efficacy for patients facing challenging treatment landscapes.
Developments in MAIA Biotechnology
MAIA Biotechnology continues to forge ahead with a promising research agenda, focusing on its objective of delivering first-in-class therapies that enhance cancer treatment. The clinical focus remains on ateganosine, developed specifically for NSCLC patients whose treatment options have been exhausted from prevailing therapies.
Contact Information for Investor Relations
For further inquiries, please contact:
+1 (872) 270-3518
ir@maiabiotech.com
Frequently Asked Questions
What is the purpose of the THIO-101 clinical trial?
The THIO-101 trial aims to evaluate the safety and efficacy of ateganosine as a treatment for NSCLC patients who have not adequately responded to prior therapies.
How many patients have been enrolled in the THIO-101 trial?
As of the latest updates, 12 patients have been enrolled in the THIO-101 expansion trial.
What are the expected benefits of ateganosine in treating cancer?
Ateganosine is designed to target telomeres, promoting cancer cell death and enhancing immune responses, potentially transforming treatment protocols for lung cancer.
Who is leading the clinical trials for MAIA?
The trials are led by various experienced medical professionals, including Dr. Victor Zaporojan and Dr. Vlad Vitoc, who oversee the strategic direction and execution of the studies.
How can interested individuals obtain more information about the trials?
Individuals can learn more about the clinical trials by visiting ClinicalTrials.gov or MAIA’s official website for detailed reports and updates.
